ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView.
The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cancer that could ultimately enable hospitals worldwide to access technology that measures HER2 status in breast cancer patients.
Newlands says it has opened up "a major market opportunity" with the partnership.